34 results match your criteria: "David Maddison Clinical Sciences Building[Affiliation]"

Ljungan virus (LV) is a suspected human pathogen recently isolated from bank voles in Sweden. This study describes the genetic characterization of a virus, M1146, which was isolated in 1962 from another vole species (Microtus montanus), trapped in Oregon, USA. Based on antigenic properties, M1146 was postulated previously as a putative member of the family PICORNAVIRIDAE: The near complete genomic sequence verifies that M1146 is a member of the Picornaviridae, most closely related to LVs isolated in Sweden.

View Article and Find Full Text PDF

Advances in the non-surgical treatment of melanoma.

Expert Opin Investig Drugs

January 2002

Immunology and Oncology Unit, Room 443, David Maddison Clinical Sciences Building, Cnr. King & Watt Streets, Newcastle, NSW 2300, Australia.

Immune responses appear to play a role in the natural history of melanoma and immunotherapy has therefore been the subject of a number of studies. The results of several large randomised studies using allogeneic melanoma vaccines have shown minimal benefit and Phase I/II studies with gene transfected melanoma cells do not appear particularly encouraging. The majority of current interest now centres on development of vaccines using defined melanoma antigens recognised by T-cells and given as dendritic vaccines or injected directly as melanoma peptides or DNA.

View Article and Find Full Text PDF

A prognostic index for 30-day mortality after stroke.

J Clin Epidemiol

August 2001

Centre for Clinical Epidemiology and Biostatistics, David Maddison Clinical Sciences Building, Royal Newcastle Hospital, Newcastle, New South Wales 2300, Australia.

The objective of this study was to develop a simplified scoring system to predict 30-day mortality in patients with acute ischemic stroke. A retrospective cohort study was performed in a tertiary referral hospital in the Hunter Region of Australia. A prognostic index was created by assigning points to the variables in a Cox model.

View Article and Find Full Text PDF

Previous studies have shown that activation of NF-kappaB can inhibit apoptosis induced by a number of stimuli. It is also known that TNF-related apoptosis-inducing ligand (TRAIL) can activate NF-kappaB through the death receptors TRAIL-R1 and TRAIL-R2, and decoy receptor TRAIL-R4. In view of these findings, we have investigated the extent to which activation of NF-kappaB may account for the variable responses of melanoma lines to apoptosis induced by TRAIL and other TNF family members.

View Article and Find Full Text PDF

Mortality after acute myocardial infarction is lower in metropolitan regions than in non-metropolitan regions.

J Epidemiol Community Health

August 2000

Centre for Clinical Epidemiology and Biostatistics, The University of Newcastle, David Maddison Clinical Sciences Building, Royal Newcastle Hospital, Newcastle NSW 2300, Australia.

Study Objectives: To compare in-hospital mortality for acute myocardial infarction (AMI) between metropolitan and non-metropolitan hospitals after adjustment for patients' severity; to examine the role of the use of effective cardiac medications in the possible mortality difference between these types of hospital.

Design: Retrospective cohort study.

Setting: 47 acute public hospitals in metropolitan and non-metropolitan areas of New South Wales, Australia, taking part in the Acute Cardiac Care Project based on medical record review.

View Article and Find Full Text PDF

Immunogenicity of CD63 in a patient with melanoma.

Melanoma Res

August 1997

Oncology and Immunology Unit, David Maddison Clinical Sciences Building, Newcastle, NSW, Australia.

CD63 is a member of the tetraspan family of molecules that is expressed in melanoma and which appears to be involved in regulation of motility and adhesion of melanoma cells. In the present study we have screened a cDNA library from a melanoma cell with antisera from a patient with melanoma and have shown that one of the antigens identified was CD63. The clone isolated contained a mutation in the transmembrane region, but this did not appear to be involved in immunogenicity of the molecule.

View Article and Find Full Text PDF

Melanoma vaccines: prospects for the treatment of melanoma.

Expert Opin Investig Drugs

March 1997

Oncology & Immunology Unit, Department of Surgery, John Hunter Hospital, Room 443, David Maddison Clinical Sciences Building, Cnr.King & Watt Street, Newcastle, NSW2300, Australia.

A number of melanoma vaccines, made from whole melanoma cells or components of melanoma cells, are being tested in Phase II or III trials in patients after surgical removal of high risk primary or regional lymph node metastases, or in those with disseminated melanoma. During the progress of these trials, a number of melanoma antigens and their peptide epitopes that are recognised by human T-cells have been described. These findings and new information about antigen recognition by human T-cells have made it possible to explore the use of peptide epitopes targeted at T-cells as melanoma vaccines.

View Article and Find Full Text PDF

CD63 belongs to the Transmembrane 4 superfamily (TM4SF) of membrane proteins whose functions are largely unknown. Previous results have suggested that CD63 may play an important role in the regulation of melanoma progression. To explore the role of CD63 in melanoma we have examined its association with other molecules by immunoprecipitation of CD63 from detergent induced lysates of melanoma cells.

View Article and Find Full Text PDF

The receptors involved in apparently nonspecific, MHC- unrestricted effector cell-target cell interaction and lysis continue to raise controversy. They bind to distinct ligands on their target cells and activate diverse cellular functions such as gene expression, lymphokine production, proliferation and/or cytolytic activity by the effector cells. Several distinct receptors may mediate MHC-unrestricted cytotoxicity.

View Article and Find Full Text PDF